DrugDashboards

pantoprazole sodium

pantoprazole sodium · PANTOPRAZOLE SODIUM 40 mg/1 · Injection, Powder, For Solution · Intravenous · Camber Pharmaceuticals, Inc.

NDC 31722-0204-32 · 25 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

13 companies supply this market — deep enough that no single failure threatens the supply. Historically, drugs in this position went on to a new shortage within 90 days about 0.7% of the time — roughly 4× the typical drug (0.1%).

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.7%chance of a new FDA shortage posting for pantoprazole sodium (injectable) in the next 90 days

sterile injectable · price up 28% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 4× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $12.94 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA213778
TE code
AP
Approval date
May 18, 2022
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of pantoprazole sodium (Injection, Powder, For Solution)

LabelerStrengthFirst seenLast seen
Meitheal Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 3, 2026
BE Pharmaceuticals Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.PANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Cardinal Health 107, LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Devatis Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Northstar Rx LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Piramal Critical CarePANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Sandoz IncPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Takeda GmbHPANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Sep 2, 2026
Wasserburger Arzneimittelwerk GmbHPANTOPRAZOLE SODIUM 40 mg/1Jul 15, 2026Sep 2, 2026
Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.PANTOPRAZOLE SODIUM 40 mg/10mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "pantoprazole sodium — NDC 31722-0204-32," retrieved September 3, 2026, https://drugdashboards.com/drug/31722020432.

Free to cite with attribution — see how the data is put together.